Citigroup
PBE icon

Citigroup’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Citigroup’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9K Hold
150
– – ﹤0.01% 4973
2025
Q4 		$12.3K Buy
+150
New +$11.6K ﹤0.01% 4997
2025
Q3 		– Sell
-200
Closed -$12.8K – 6258
2025
Q2 		$12.8K Hold
200
– – ﹤0.01% 5148
2025
Q1 		$12.7K Hold
200
– – ﹤0.01% 5158
2024
Q4 		$13.3K Sell
200
-500
-71% -$34.5K ﹤0.01% 5328
2024
Q3 		$48.9K Hold
700
– – ﹤0.01% 5030
2024
Q2 		$45.4K Sell
700
-150
-18% -$9.5K ﹤0.01% 4640
2024
Q1 		$55K Hold
850
– – ﹤0.01% 4580
2023
Q4 		$56K Hold
850
– – ﹤0.01% 4461
2023
Q3 		$48.5K Hold
850
– – ﹤0.01% 4154
2023
Q2 		$52.1K Hold
850
– – ﹤0.01% 4624
2023
Q1 		$53.4K Sell
850
-452
-35% -$29.1K ﹤0.01% 4240
2022
Q4 		$82.7K Hold
1,302
– – ﹤0.01% 4095
2022
Q3 		$77K Hold
1,302
– – ﹤0.01% 4209
2022
Q2 		$75K Hold
1,302
– – ﹤0.01% 4354
2022
Q1 		$81K Sell
1,302
-563
-30% -$34.4K ﹤0.01% 4514
2021
Q4 		$133K Sell
1,865
-1,215
-39% -$88K ﹤0.01% 4584
2021
Q3 		$231K Sell
3,080
-1,931
-39% -$147K ﹤0.01% 4051
2021
Q2 		$388K Buy
5,011
+192
+4% +$14.3K ﹤0.01% 3864
2021
Q1 		$356K Buy
4,819
+25
+0.5% +$1.89K ﹤0.01% 3689
2020
Q4 		$336K Sell
4,794
-100
-2% -$6.33K ﹤0.01% 4564
2020
Q3 		$277K Sell
4,894
-800
-14% -$47K ﹤0.01% 4351
2020
Q2 		$332K Hold
5,694
– – ﹤0.01% 4615
2020
Q1 		$265K Buy
5,694
+375
+7% +$19.6K ﹤0.01% 4489
2019
Q4 		$297K Buy
5,319
+25
+0.5% +$1.3K ﹤0.01% 4861
2019
Q3 		$251K Hold
5,294
– – ﹤0.01% 4952
2019
Q2 		$283K Buy
5,294
+50
+1% +$2.59K ﹤0.01% 4970
2019
Q1 		$289K Buy
5,244
+100
+2% +$5.29K ﹤0.01% 4739
2018
Q4 		$242K Buy
5,144
+740
+17% +$38K ﹤0.01% 4830
2018
Q3 		$262K Buy
4,404
+50
+1% +$2.92K ﹤0.01% 4961
2018
Q2 		$238K Buy
4,354
+100
+2% +$5.08K ﹤0.01% 4882
2018
Q1 		$209K Buy
4,254
+50
+1% +$2.55K ﹤0.01% 4926
2017
Q4 		$198K Buy
4,204
+250
+6% +$11.7K ﹤0.01% 5052
2017
Q3 		$197K Buy
3,954
+875
+28% +$41.5K ﹤0.01% 5004
2017
Q2 		$141K Buy
3,079
+202
+7% +$8.72K ﹤0.01% 5073
2017
Q1 		$122K Sell
2,877
-601
-17% -$25.2K ﹤0.01% 5058
2016
Q4 		$135K Sell
3,478
-1,202
-26% -$48.5K ﹤0.01% 5586
2016
Q3 		$196K Hold
4,680
– – ﹤0.01% 4674
2016
Q2 		$173K Sell
4,680
-3,515
-43% -$138K ﹤0.01% 4621
2016
Q1 		$314K Sell
8,195
-1,100
-12% -$42.7K ﹤0.01% 4644
2015
Q4 		$470K Sell
9,295
-499
-5% -$24.7K ﹤0.01% 3925
2015
Q3 		$448K Sell
9,794
-499
-5% -$27.9K ﹤0.01% 3845
2015
Q2 		$601K Buy
10,293
+901
+10% +$51.5K ﹤0.01% 3541
2015
Q1 		$517K Buy
9,392
+236
+3% +$12.8K ﹤0.01% 3712
2014
Q4 		$460K Buy
9,156
+831
+10% +$40.7K ﹤0.01% 3964
2014
Q3 		$385K Sell
8,325
-42
-0.5% -$1.89K ﹤0.01% 3731
2014
Q2 		$366K Buy
8,367
+1,399
+20% +$56.7K ﹤0.01% 3666
2014
Q1 		$290K Buy
6,968
+3,630
+109% +$155K ﹤0.01% 3975
2013
Q4 		$124K Buy
3,338
+1,134
+51% +$40.7K ﹤0.01% 5073
2013
Q3 		$77K Hold
2,204
– – ﹤0.01% 4937
2013
Q2 		$64K Buy
+2,204
New +$62.7K ﹤0.01% 5205

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Citigroup's PBE Position: Q1 2026 in Review

Citigroup held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 150 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4973.

Citigroup first reported a position in PBE in Q2 2013 and has held it in 51 quarters since. The position peaked at $601K in Q2 2015. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • Citigroup held 150 shares of Invesco Biotechnology & Genome ETF worth $11.9K as of Q1 2026.
  • Citigroup left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4973 holding.
  • Citigroup first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 51 quarters since.
  • Citigroup's Invesco Biotechnology & Genome ETF position peaked at $601K in Q2 2015.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.